Drug Profile
AS 900672-Enriched
Alternative Names: AS900672-Enriched; Follicle-stimulating hormone analogue - Merck Serono; FSH analogue - Merck Serono; Glycosylated recombinant follicle-stimulating hormone; Glycosylated recombinant FSH; Hyperglycosylated FSH - Merck Serono; Long-acting follicle stimulating hormone - Merck Serono; Long-acting FSH - Merck SeronoLatest Information Update: 07 Aug 2015
Price :
$50
*
At a glance
- Originator Merck Serono
- Developer EMD Serono
- Class Follicle stimulating hormones; Infertility therapies; Pituitary gonadotropins
- Mechanism of Action Ovarian follicle stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Female infertility
Most Recent Events
- 30 Sep 2008 Merck KGaA completes a phase II trial for Female infertility in USA (NCT00505752)
- 03 Jul 2007 Phase I development is ongoing for Female infertility
- 08 Jan 2007 Serono is now called Merck Serono